NCT07166315
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 3 words
- Primary and study completion pushed from Mar 2027 to Jul 31, 2027
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
Timeframe: At 12 months
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
Timeframe: At 12 months
Change from baseline in PROM scores at 12 months.
Timeframe: At 12 months
Arms and interventions
Axial spondyloarthritis (axSpA)
Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.
Psoriatic arthritis (PsA)
Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.
Other: observational study
Sites
1 site in 1 country
- Royal National Hospital for Rheumatic DiseasesBath, Somerset, United Kingdom